{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:31:59Z","timestamp":1784097119016,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1135837"],"award-info":[{"award-number":["GNT1135837"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2001278"],"award-info":[{"award-number":["GNT2001278"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020821","name":"Monash Biomedicine Discovery Institute, Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.biopha.2023.114370","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T05:52:09Z","timestamp":1675662729000},"page":"114370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-1372","authenticated-orcid":false,"given":"Fariha","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey A.","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara K.","family":"Kemp-Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-7083","authenticated-orcid":false,"given":"Edward","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-5885","authenticated-orcid":false,"given":"Aaron","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Ferens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iresha","family":"Spizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Maree","family":"Jefferis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Praveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Widdop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.D.","family":"Bathgate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Akhter","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrishan S.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114370_bib1","unstructured":"World Health Organisation , (2021) \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)\u3009. (Accessed 30 January 2023)."},{"key":"10.1016\/j.biopha.2023.114370_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","article-title":"Cardioprotective actions of relaxin","volume":"487","author":"Martin","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114370_bib4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.drudis.2020.04.014","article-title":"Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target","volume":"25","author":"Bani","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2023.114370_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114884","article-title":"Relaxin as an anti-fibrotic treatment: perspectives, challenges and future directions","volume":"197","author":"Samuel","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1096\/fj.01-0070com","article-title":"The pregnancy hormone relaxin is a player in human heart failure","volume":"15","author":"Dschietzig","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.114370_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11906-011-0231-x","article-title":"Effects of relaxin on arterial dilation, remodeling, and mechanical properties","volume":"13","author":"Conrad","year":"2011","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.biopha.2023.114370_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00001.2012","article-title":"Relaxin family peptides and their receptors","volume":"93","author":"Bathgate","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2023.114370_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ajodo.2011.07.024","article-title":"A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability","volume":"141","author":"McGorray","year":"2012","journal-title":"Am. J. Orthod. Dentofac. Orthop."},{"key":"10.1016\/j.biopha.2023.114370_bib10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.24380","article-title":"Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Khanna","year":"2009","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.biopha.2023.114370_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114370_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","volume":"381","author":"Metra","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.biopha.2023.114370_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.114370_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cbpa.2014.09.014","article-title":"Synthetic relaxins","volume":"22","author":"Hossain","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.biopha.2023.114370_bib15","doi-asserted-by":"crossref","first-page":"37555","DOI":"10.1074\/jbc.M111.282194","article-title":"The minimal active structure of human relaxin-2","volume":"286","author":"Hossain","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114370_bib16","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1039\/C5SC04754D","article-title":"A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1","volume":"7","author":"Hossain","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.biopha.2023.114370_bib17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1096\/fj.08-120857","article-title":"Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2","volume":"23","author":"Mookerjee","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.114370_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.2013.518","article-title":"Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis","volume":"86","author":"Chow","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2023.114370_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2016.00091","article-title":"The anti-fibrotic actions of relaxin are mediated through a NO-sGC-cGMP-Dependent pathway in renal myofibroblasts in vitro and enhanced by the NO donor, diethylamine NONOate","volume":"7","author":"Wang","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib20","doi-asserted-by":"crossref","first-page":"10681","DOI":"10.1016\/S0021-9258(18)87000-4","article-title":"Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts","volume":"265","author":"Unemori","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114370_bib21","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI119099","article-title":"Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo","volume":"98","author":"Unemori","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.114370_bib22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1582-4934.2007.00111.x","article-title":"Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling","volume":"11","author":"Formigli","year":"2007","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2023.114370_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042714","article-title":"Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS","volume":"7","author":"Chow","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114370_bib24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.12247","article-title":"Relaxin decreases the severity of established hepatic fibrosis in mice","volume":"34","author":"Bennett","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2023.114370_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10741-009-9135-0","article-title":"A novel approach to improve cardiac performance: cardiac myosin activators","volume":"14","author":"Teerlink","year":"2009","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2023.114370_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015748","article-title":"B7-33, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice","volume":"9","author":"Devarakonda","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2023.114370_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2017.05.005","article-title":"B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin)","volume":"807","author":"Marshall","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000524722","article-title":"Metabolic and metabolomics insights into dilated cardiomyopathy","volume":"78","author":"Ampong","year":"2022","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.biopha.2023.114370_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/CS20070365","article-title":"Higher levels of collagen and facilitated healing protect against ventricular rupture following myocardial infarction","volume":"115","author":"Fang","year":"2008","journal-title":"Clin. Sci"},{"key":"10.1016\/j.biopha.2023.114370_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1152\/physiolgenomics.00071.2010","article-title":"Influence of genetic background on ex vivo and in vivo cardiac function in several commonly used inbred mouse strains","volume":"42A","author":"Barnabei","year":"2010","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.biopha.2023.114370_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","article-title":"Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease","volume":"64","author":"Samuel","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2023.114370_bib32","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/bph.15428","article-title":"Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy-induced ventricular remodelling and dysfunction","volume":"178","author":"Wang","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10557-005-5059-7","article-title":"Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats","volume":"18","author":"Nagai","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.biopha.2023.114370_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168425","article-title":"The effects of rilmenidine and perindopril on arousal blood pressure during 24\u2009h recordings in SHR","volume":"11","author":"Lim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114370_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cvr\/cvm021","article-title":"Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice","volume":"77","author":"Vinh","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.114370_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00210-013-0920-x","article-title":"Hydrogen sulfide protects endothelial nitric oxide function under conditions of acute oxidative stress in vitro","volume":"387","author":"Al-Magableh","year":"2014","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib37","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002053RRR","article-title":"Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform","volume":"35","author":"Bhuiyan","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.114370_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2019.01.008","article-title":"Single chain peptide agonists of relaxin receptors","volume":"487","author":"Praveen","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114370_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cvr\/cvu062","article-title":"Crosstalk between fibroblasts and inflammatory cells","volume":"102","author":"Van Linthout","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2023.114370_bib40","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1681\/ASN.2019060597","article-title":"AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: impact on the therapeutic targeting of renal and cardiac fibrosis","volume":"30","author":"Chow","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114370_bib41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/acsptsci.9b00095","article-title":"Serelaxin and the AT2 receptor agonist CGP42112 evoked a similar, nonadditive, cardiac antifibrotic effect in high salt-fed mice that were refractory to candesartan cilexetil","volume":"3","author":"Wang","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2023.114370_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-008-9129-3","article-title":"Relaxin, a pleiotropic vasodilator for the treatment of heart failure","volume":"14","author":"Teichman","year":"2008","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2023.114370_bib43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/bph.13695","article-title":"Serelaxin in clinical development: past, present and future","volume":"174","author":"Unemori","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mce.2019.01.013","article-title":"Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): rationale for future clinical trials","volume":"487","author":"Dschietzig","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114370_bib45","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/0140-6736(92)90665-P","article-title":"Cardiac effects of relaxin in rats","volume":"339","author":"Kakouris","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114370_bib46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.RES.74.3.537","article-title":"Relaxin increases heart rate by modulating calcium current in cardiac pacemaker cells","volume":"74","author":"Han","year":"1994","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2023.114370_bib47","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/1097-0142(19920801)70:3<639::AID-CNCR2820700316>3.0.CO;2-V","article-title":"Relaxin influences the growth of MCF-7 breast cancer cells. Mitogenic and antimitogenic action depends on peptide concentration","volume":"70","author":"Bigazzi","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.114370_bib48","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1074\/jbc.M114.589325","article-title":"Relaxin activates peroxisome proliferator-activated receptor gamma (PPARgamma) through a pathway involving PPARgamma coactivator 1alpha (PGC1alpha)","volume":"290","author":"Singh","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114370_bib49","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bph.12964","article-title":"Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins","volume":"172","author":"Sarwar","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib50","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41598-017-02916-5","article-title":"ML290 is a biased allosteric agonist at the relaxin receptor RXFP1","volume":"7","author":"Kocan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114370_bib51","doi-asserted-by":"crossref","first-page":"7074","DOI":"10.3390\/ijms23137074","article-title":"Relaxin inhibits the cardiac myofibroblast NLRP3 inflammasome as part of its anti-fibrotic actions via the angiotensin type 2 and ATP (P2X7) receptors","volume":"23","author":"Tapia Caceres","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.114370_bib52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.34067\/KID.0002722021","article-title":"Relaxin attenuates organ fibrosis via an angiotensin type 2 receptor mechanism in aged hypertensive female rats","volume":"360","author":"Barsha","year":"2021","journal-title":"Kidney"},{"key":"10.1016\/j.biopha.2023.114370_bib53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjp.0706749","article-title":"Changes in vascular reactivity following administration of isoproterenol for 1 week: a role for endothelial modulation","volume":"148","author":"Davel","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FJC.0b013e31818a8927","article-title":"Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats","volume":"52","author":"Fukuda","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib55","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1476-5381.1995.tb15096.x","article-title":"Endothelium-dependent relaxations in sheep pulmonary arteries and veins: resistance to block by NG-nitro-L-arginine in pulmonary hypertension","volume":"116","author":"Kemp","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.fjc.0000175879.14994.63","article-title":"Altered vascular reactivity in mice made hypertensive by nitric oxide synthase inhibition","volume":"46","author":"Linder","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjp.0704683","article-title":"Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db\/db -\/-) mice: role of decreased tetrahydrobiopterin bioavailability","volume":"136","author":"Pannirselvam","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib58","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/sj.bjp.0706121","article-title":"Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products","volume":"144","author":"Pannirselvam","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114370_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091877","article-title":"Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a Gialpha-coupled beta2-adrenoceptor signaling pathway","volume":"9","author":"Davel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114370_bib60","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1210\/en.2010-1126","article-title":"Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide","volume":"152","author":"McGuane","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2023.114370_bib61","doi-asserted-by":"crossref","first-page":"R349","DOI":"10.1152\/ajpregu.00635.2001","article-title":"Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats","volume":"283","author":"Novak","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2023.114370_bib62","doi-asserted-by":"crossref","first-page":"H488","DOI":"10.1152\/ajpheart.00244.2020","article-title":"Chronic stress and endothelial dysfunction: mechanisms, experimental challenges, and the way ahead","volume":"319","author":"Sher","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223001580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223001580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:47:47Z","timestamp":1776772067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223001580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":62,"alternative-id":["S0753332223001580"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114370","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114370"}}